SEC Filing Madrigal Pharmaceuticals.
4.5
(220)
Write Review
More
$ 20.50
In stock
Description
HC Wainwright Adjusts Madrigal Pharmaceuticals' Price Target to $275 From $225, Maintains Buy Rating -November 13, 2023 at 09:30 am EST
SEC Filing Kiniksa Pharmaceuticals
Madrigal Pharmaceuticals Announces FDA Approval of
DEF 14A
g113954mmi004.gif
SEC Filing Madrigal Pharmaceuticals.
Overview Madrigal Pharmaceuticals.
SEC Filing Madrigal Pharmaceuticals.
SEC Filing
g560783.jpg
ETFs Holding MDGL, Madrigal Pharmaceuticals Inc
SEC Filing Terns Pharmaceuticals, Inc.
Overview Madrigal Pharmaceuticals.
You may also like
)
